Publication | Closed Access

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Diabetes ManagementDiabetesPharmacologyClinical TrialsType 2Treatment OptionPharmacotherapyDiabetes MellitusDaily Versus ExenatideMedicinePhase 3